This inventor holds 1 USPTO granted patent. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004
Title: Sarkiz D Issankani: Innovator in HCV Treatment
Introduction
Sarkiz D Issankani is a notable inventor based in San Jose, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Hepatitis C virus (HCV) infections. His innovative work has the potential to impact many lives by providing effective treatment options.
Latest Patents
Issankani holds a patent for "Substituted diphenyl heterocycles useful for treating HCV infection." This invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions that inhibit the replication of the HCV virus. The compounds and compositions developed by Issankani are designed to treat or prevent HCV infections, showcasing his commitment to advancing medical science.
Career Highlights
Sarkiz D Issankani is currently associated with Rigel Pharmaceuticals, Incorporated, where he continues to work on innovative solutions in the pharmaceutical industry. His expertise and dedication have positioned him as a valuable asset in the field of drug development.
Collaborations
Issankani collaborates with talented professionals in his field, including Rajinder Paul Singh and Dane A Goff. These partnerships enhance the research and development efforts at Rigel Pharmaceuticals, fostering an environment of innovation.
Conclusion
Sarkiz D Issankani is a prominent inventor whose work in HCV treatment exemplifies the importance of innovation in healthcare. His contributions are paving the way for new therapeutic options that could benefit countless individuals affected by HCV.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile